Video Journal of Oncology (VJOncology)

NEW #podcast episode: 'Updates in #immunotherapy for #skincancer’ 🎧 In this episode we cover: 🔦 Impact of T-Cell therapies, such as #lifileucel, in patients with #melanoma 🔦 Results of the 7-year CheckMate 238 trial (NCT02388906) of #nivolumab 🔦 Effective #sequencing of treatments in the #SECOMBITtrial (NCT02631447) 🔦 Challenges in managing immunotherapy related #adverseevents With leading experts:  🌟 Omid Hamid, MD, The Angeles Clinic & Research Institute, Inc. 🌟 Paolo A. Ascierto, MD, IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy 🌟 Georgina Long, PhD, MBBS, FRACP, FAHMS, Medicine and Health - University of Sydney 🌟 Karijn Suijkerbuijk, MD, PhD, UMC Utrecht Give it a listen 👉https://lnkd.in/eqnYMHRa Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJOncology

NEW from #SABCS2024 | DECRESCENDO: de-escalating #chemotherapy in #HER+, #HR- early #breastcancer 🎥 🇺🇸 Elisa Agostinetto, MD, Jules Bordet Institute, discusses findings from the Phase II DECRESCENDO trial (NCT04675827) of #anthracycline-free treatment for #HER2-positive, #HR-negative, node-negative early #breastcancer Patients received #neoadjuvant #taxane-based therapy with #pertuzumab and #trastuzumab, achieving a high pathologic complete response. Although terminated early due to slow recruitment, the study demonstrates the potential of de-escalated regimens to maintain efficacy while minimizing long-term chemotherapy-related toxicity 🌟 Learn more 👉 https://lnkd.in/e7sgtuWE #VJOncology #Oncologynews

NEW #podcast episode: '#Antibody drug conjugates in #gastrointestinalcancers’ 🎧 We are joined by: 🌟 Kohei Shitara (National Cancer Center Hospital East) 🌟 Yelena Janjigian (Memorial Sloan Kettering Cancer Center) 🌟 John Strickler (Duke Cancer Institute) 🌟 Scott Kopetz (MD Anderson Cancer Center) Highlights include novel treatment strategies in #HER2-expressing #gastriccancer, findings from the #DESTINY-Gastric03 and ABBV-400 trials, and the role of CEACAM5-targeting ADCs in #colorectalcancer Give it a listen 👉 https://lnkd.in/eJygWigg Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJOncology #Oncologynews #CRCsm

Prof. Dr. med. Hans-Christian Kolberg, MD, Marienhospital Bottrop discusses the NeoMono trial in #TNBC at #SABCS24 🇺🇸 🎥 🌟High PCR rates in PD-L1+ patients 🌟PD-L1 = key biomarker for #immune checkpoint therapy Take a look 👉 https://ow.ly/WgIu50Ur1Rj #BreastCancer #BCSM #ImmunoOnc #CTSM #TrialUpdates

From my interview with Video Journal of Oncology (VJOncology) in San Antonio Breast Cancer Symposium to discuss our study.

🚨🇺🇸 Day 1 of #SABCS24 has arrived, so be sure keep an eye out for our #breastcancer coverage live from San Antonio 🗞️ 🎥 Keep and eye on this page for exclusive interviews with the speakers 👉 https://lnkd.in/eZRnhkt8 #Oncologynews #VJOncology #bcsm

NEW SMR 2024 | Results from a pilot trial evaluating #lifileucel in #melanoma #brainmetastases 🎥 Allison Betof Warner, MD, Stanford Cancer Center, shares results from a pilot trial (NCT05640193) that demonstrated the feasibility of #lifileucel for active #melanoma #brainmetastases (MBM) All patients successfully completed the trial without presenting complications like #seizures or #intracranialhemorrhage, and the safety of the modified treatment regimen resembled the standard #lifileucel regimen 🌟 A majority of patients who underwent #surgical excision successfully received the lifileucel infusion. Dr Warner concludes that although the pilot trial showed promising results, further expansion of this trial with careful selection of patients is necessary to ensure the complete safety and efficacy of lifileucel 🔎 Learn more 👉 https://lnkd.in/em3DsDHi #SkcSM #SkinCancer #Oncologynews #VJOncology

NEW Dermato-Onco2024 | Addressing potential #biases in #AI models for #skincancer diagnosis 🎥 Harald Kittler, MD, Medical University of Vienna, highlights biases that could interfere with accurate diagnosis of #skincancers using #artificialintelligence (#AI) models 🔦 #Systemicbias can lead to the #underdiagnosis or #overdiagnosis of a disease. Training data sets for #AIdiagnosis models may exclude underrepresented patient cohorts based on age, sex, or ethnicity, or contain the #histopathology of specific #diseasesubtypes, which are not well defined and lead to #misdiagnosis A potential solution would be to incorporate a more diverse and inclusive patient cohort in the training datasets for AI diagnosis of skin cancers 🌟 Learn more 👉 https://lnkd.in/eKrY_5xH #SkcSM #SkinCancer #Oncologynews #VJOncology

#SABCS24 is approaching quickly, and we’re so excited to cover the event here at @VJOncology! 🎥🗞️🇺🇸 📆 From December 10th-13th, experts will deliver all the key updates in #breastcancer, don’t miss out! Stay updated 👉 https://lnkd.in/eZRnhkt8 #BCsm #VJOncology #Oncologynews

Very nice to have been included here with some big hitters, does nothing for my imposter syndrome. With #LungCancer awareness month coming to a close it’s time to reflect on all the great work done globally to advance the field. But specifically the work done in the UK is significant in my view. Having just returned home from the Cruk Lung Cancer Centre of Excellence meeting I am reflecting on all the great work done there and at other institutions around the country. Lots of progress, but we still need more basic research, more discovery, more trials and all with the same level of compassion for our patients, our colleagues and ourselves.